Table 3. Univariate analyses of overall survival.
N | 2-year OS | (95%CI) | p | |
---|---|---|---|---|
All patients | 67 | 24% | (15-37) | |
Cytogenetics | ||||
Intermediate | 35 | 27% | (15-49) | 0.351 |
Unfavorable | 32 | 20% | (10-41) | |
Intermediate risk | ||||
ASXL1-wt | 21 | 37% | (20-70) | 0.030 |
ASXL1-mut | 14 | 14% | (4-52) | |
Unfavorable risk | ||||
TP53-wt | 21 | 26% | (12-56) | 0.040 |
TP53-mut | 11 | 9% | (1-59) | |
Genotype | ||||
No mutation | 41 | 29% | (17-49) | 0.005 |
ASXL1 or TP53 mut | 26 | 15% | (7-38) |